Article
Oncology
Catarina Nascimento, Andreia Gameiro, Joao Ferreira, Jorge Correia, Fernando Ferreira
Summary: Feline mammary carcinoma is the third most common neoplasia in cats, with highly malignant behavior. The study suggests that VEGF-A and its serum receptors assessment may have potential in the diagnosis and treatment of feline mammary carcinoma.
Review
Chemistry, Medicinal
Die Jiang, Ting Xu, Lei Zhong, Qi Liang, Yonghe Hu, Wenjing Xiao, Jianyou Shi
Summary: Angiogenesis is a vital biological process for body growth and development, wound healing, and tissue formation. Dysregulation of VEGFR signaling can lead to diseases, making it a crucial research area for disease treatment. Currently, anti-VEGF drugs used in ophthalmology have limitations, and there is a need to develop small molecule inhibitors of VEGFR for the targeted treatment of ocular neovascularization diseases.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Jose Luis Castaneda-Cabral, Sandra A. Orozco-Suarez, Carlos Beas-Zarate, Blanca F. Fajardo-Fregoso, Mario E. Flores-Soto, Monica E. Urena-Guerrero
Summary: This study aimed to evaluate the effects of VEGFR-2 inhibition on neuronal damage induced by neonatal MSG treatment. The inhibition of VEGFR-2 signaling increased the neuronal damage caused by MSG treatment, and MSG treatment increased the expression levels of VEGF-A/VEGFR-2 signaling pathway proteins, particularly in the cerebral motor cortex.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
(2023)
Review
Pharmacology & Pharmacy
Ivan Guryanov, Tatiana Tennikova, Arto Urtti
Summary: VEGFs play crucial roles in angiogenesis, but dysregulation can lead to pathological angiogenesis in various diseases. Monoclonal antibodies and decoy receptors are commonly used to neutralize VEGFA in anti-angiogenic therapies. Short peptides are promising alternatives to full-length VEGFA inhibitors, overcoming some limitations of existing therapies.
Review
Biochemistry & Molecular Biology
Peace Mabeta, Vanessa Steenkamp
Summary: The VEGF/VEGFR axis plays a crucial role in angiogenesis and tumor vascularization. Current therapies targeting VEGF and its receptors have shown limited effectiveness and undesirable off-target effects. Recent studies have identified VEGF splice variants that modulate angiogenesis, and their expression is regulated by cues within the tumor microenvironment. These variants challenge the established norm of VEGF signaling and their aberrant expression has been observed in several cancers, highlighting the need for further research on their role in cancer and their impact on antiangiogenic therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Lorenzo Fornaro, Gianna Musettini, Paola Orlandi, Irene Pecora, Caterina Vivaldi, Marta Banchi, Francesca Salani, Elisabetta Fini, Valentina Massa, Silvia Catanese, Federico Cucchiara, Monica Lencioni, Gianluca Masi, Enrico Vasile, Guido Bocci
Summary: Ramucirumab plus paclitaxel is considered standard treatment for second-line gastric carcinoma (GC) patients. This study evaluated plasma VEGF-A, VEGF-D, and sVEGFR-2 as potential markers of resistance or response to this treatment. Results showed significant increases in VEGF-A and VEGF-D levels during treatment, and early increase in sVEGFR-2 levels was associated with longer progression-free survival and overall survival.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Zhibao Wang, Bo Cao, Peng Ji, Fan Yao
Summary: Propofol inhibits tubular structure formation and various biological functions of tumor-associated endothelial cells, including migration, adhesion, proliferation, and survival, by suppressing the expression and secretion of multiple pro-angiogenic factors and specific signaling pathways. These findings provide preclinical evidence for the anti-cancer properties of propofol and its potential mechanisms in inhibiting tumor growth and metastasis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Oncology
Laura Micheli, Carmen Parisio, Elena Lucarini, Alessia Vona, Alessandra Toti, Alessandra Pacini, Tommaso Mello, Serena Boccella, Flavia Ricciardi, Sabatino Maione, Grazia Graziani, Pedro Miguel Lacal, Paola Failli, Carla Ghelardini, Lorenzo Di Cesare Mannelli
Summary: Studies in murine models suggest that VEGF-A and its receptor VEGFR-1 play a crucial role in chemotherapy-induced neuropathic pain, mediating pain transmission through communication between astrocytes and neurons. Blocking VEGFR-1 may help alleviate neuropathic pain by disrupting this interaction.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Cell Biology
Kajohnkiart Janebodin, Rakchanok Chavanachat, Aislinn Hays, Morayma Reyes Gil
Summary: The study aimed to investigate the role of VEGFR-2 in odontoblast differentiation of dental pulp stem cells (DPSCs) by knocking down the expression of VEGFR-2. The results showed that VEGFR-2 is crucial for odontoblast differentiation in DPSCs, and deficiency of VEGFR-2 may impair the differentiation of odontoblast cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Reproductive Biology
Rodrigo Gonz Lopez, David Alejandro Contreras Caro del Castillo, Griselda Valdez Magana, Rosa Elena Sarmiento Silva, Francisco Ernesto Martinez Castaneda, Maria Elena Trujillo Ortega
Summary: This study investigates the mRNA expression and protein localization of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in the endometrium during the estrous cycle and peri-implantation period in sows. The results show that VEGF and VEGFR2 are present in various cells and tissues of the uterus, while VEGFR1 is mainly localized in the blood vessels and stroma. The mRNA expression levels of VEGF, VEGFR1, and VEGFR2 increase during gestation, and the selective inhibition of VEGFR2 in endometrial epithelial cells leads to a decrease in the expression of VEGFR1 and VEGFR2 mRNA.
Article
Oncology
Maria Grazia Atzori, Claudia Ceci, Federica Ruffini, Manuel Scimeca, Rosella Cicconi, Maurizio Mattei, Pedro Miguel Lacal, Grazia Graziani
Summary: The study indicates that inhibiting the activation of VEGFR-1 by PlGF can effectively restrain the metastatic potential of melanoma, reducing tumor invasiveness and tropism toward bone tissue.
Article
Cell Biology
Ming-Jen Hsu, Han-Kun Chen, Jin-Cherng Lien, Yu-Han Huang, Shiu-Wen Huang
Summary: This study evaluated the anti-angiogenic properties of a new naphthoquinone derivative, PPE8, and explored its mechanisms of action. The results showed that PPE8 reduced proliferation, migration, invasion, and tube formation in human umbilical vein endothelial cells (HUVECs) induced by VEGF-A. It also inhibited micro vessel sprouting and angiogenesis in vivo. Additionally, PPE8 suppressed phosphorylation of VEGFR-2, Src, FAK, ERK1/2, and AKT in HUVECs exposed to VEGF-A, and exhibited significant decline in xenograft tumor growth. These findings suggest that PPE8 may target VEGF-A-VEGFR-2 signaling to reduce angiogenesis, making it a potential drug candidate for angiogenesis-related diseases.
Article
Biotechnology & Applied Microbiology
Khalid Alhazzani, Thiagarajan Venkatesan, Umamaheswari Natarajan, Mohammad Algahtani, Ali Alaseem, Saad Alobid, Appu Rathinavelu
Summary: The study demonstrates that F16 inhibits the VEGFR-2 signaling pathway, reduces angiogenesis and anti-apoptosis gene expressions, and inhibits the growth of colorectal cancer cells. It also shows significant anti-tumor effects in an animal model, making it a potential new therapeutic agent for treating colorectal cancer.
BIOTECHNOLOGY LETTERS
(2022)
Article
Biochemistry & Molecular Biology
Magda M. F. Ismail, Taghreed Z. Shawer, Rabab S. Ibrahim, Rasha M. Allam, Yousry A. Ammar
Summary: This study aims to explore the VEGFR-2 inhibitory activity of a novel library of quinoxalin-2-one derivatives and found that compound 7f displayed remarkable cytotoxicity against HCT-116 and MCF-7 cell lines. It also showed potential anti-migratory effect and induced apoptosis and cell cycle arrest. Molecular docking confirmed the affinity of these compounds for VEGFR-2 active site.
BIOORGANIC CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
William Lory, Bridgette Wellslager, Chao Sun, Ozlem Yilmaz, Hong Yu
Summary: S1PR2 antagonist JTE013 enhances expression of VEGFA, PDGFA, and GDF15 genes, activates TGFβ/Smad and Akt signaling, and promotes angiogenesis and alveolar bone regeneration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Yu Fan, Ke Wang
Review
Medicine, General & Internal
Li Guo, Ke Wang, Hui Zhu, Nian Liu, Daxing Zhu
Article
Oncology
Panwen Tian, Ye Wang, Weiya Wang, Yalun Li, Ke Wang, Xiaowei Cheng, Yuan Tang, Han Han-Zhang, Junyi Ye, Shannon Chuai, Weimin Li
Article
Biotechnology & Applied Microbiology
Zhi-Xin Qiu, Ping Zhou, Ke Wang
ONCOTARGETS AND THERAPY
(2019)
Article
Oncology
Yujie Liu, Hao Zeng, Ke Wang, Yalun Li, Panwen Tian, Weimin Li
Article
Multidisciplinary Sciences
Zhixin Qiu, Bingwei Ye, Ke Wang, Ping Zhou, Shuang Zhao, Weimin Li, Panwen Tian
SCIENTIFIC REPORTS
(2020)
Article
Immunology
Hong Chen, Ke Wang, Tao Yuan, Xiaoming Wang, Lan Huanng, Zhenhuan Jiang, Keyang Chen, Yuejun Du
Summary: The study found that the dual bronchodilator is superior to ICS/LABA in improving lung function and is associated with a lower risk of pneumonia in COPD patients. However, there are no significant differences in other efficacy and safety profiles between these two maintenance treatments.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Shun Lu, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Meili Sun, Liang Han, Liyun Miao, Cuimin Ding, Jiuwei Cui, Baolan Li, Yueyin Pan, Xingya Li, Feng Ye, Anwen Liu, Ke Wang, Shundong Cang, Hui Zhou, Xing Sun, David Ferry, Yong Lin, Shuyan Wang, Wen Zhang, Chengli Zhang
Summary: The study evaluated the efficacy and safety of sintilimab with or without IBI305, combined with pemetrexed and cisplatin, for treating EGFR mutated non-small-cell lung cancer patients. The interim analysis showed prolonged progression-free survival in patients treated with sintilimab plus IBI305 plus chemotherapy compared to chemotherapy alone.
Letter
Critical Care Medicine
Hong Chen, Ke Wang
Article
Oncology
Yuankai Shi, Shiman Wu, Ke Wang, Shundong Cang, Wenxiu Yao, Yun Fan, Lin Wu, Meijuan Huang, Xingya Li, Yueyin Pan, Zhixiong Yang, Bo Zhu, Gongyan Chen, Jianhua Shi, Meili Sun, Jian Fang, Lijun Wang, Zhaohong Chen, Chunling Liu, Jingzhang Li, Jiwei Liu, Shenghua Sun, Yanqiu Zhao, Yanzhen Guo, Zili Meng, Zhefeng Liu, Zhigang Han, Hong Lu, Rui Ma, Sheng Hu, Guofang Zhao, Zheng Liu, Congying Xie, Diansheng Zhong, Hui Zhao, Huiqing Yu, Longzhen Zhang, Minghong Bi, Shanyong Yi, Shuliang Guo, Tienan Yi, Wen Li, Yingcheng Lin, Yongqian Shu, Zhendong Chen, Zhongliang Guo, Michael Greco, Tingting Wang, Haijiao Shen
Summary: This study evaluated the efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M-mutated NSCLC. The results showed that Rezivertinib had promising efficacy and a favorable safety profile.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Critical Care Medicine
Shun Lu, Lin Wu, Hong Jian, Ying Cheng, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Liang Han, Meili Sun, Liyun Miao, Cuimin Ding, Jiuwei Cui, Ke Wang, Baolan Li, Xingya Li, Feng Ye, Anwen Liu, Yueyin Pan, Shundong Cang, Hui Zhou, Xing Sun, Yuping Shen, Shuyan Wang, Wen Zhang, Yue He
Summary: In the ORIENT-31 trial, the combination of sintilimab and IBI305 plus chemotherapy showed a significant improvement in progression-free survival in patients with EGFR-mutated non-small-cell lung cancer. Compared to chemotherapy alone, the addition of sintilimab to chemotherapy demonstrated a clinically meaningful benefit. Furthermore, the combination of sintilimab, IBI305, and chemotherapy continued to show a progression-free survival advantage in the second interim analysis.
LANCET RESPIRATORY MEDICINE
(2023)
Article
Critical Care Medicine
Hong Chen, Zheng-Xu Deng, Jian Sun, Qiang Huang, Lan Huang, Yong-Hong He, Chunlan Ma, Ke Wang
Summary: Inhaled therapy containing ICSs, especially triple therapy, can reduce the all-cause mortality risk in patients with COPD. Predictors of this association include medication factors and patient characteristics, with eosinophil counts of ≥200/mL being the strongest predictor.
Review
Geriatrics & Gerontology
Hong Chen, Zhibo Xu, Jing Yang, Lan Huang, Ke Wang
Summary: This meta-analysis showed that the use of ICS does not increase the risk of influenza in patients with asthma. Different doses and types of ICS treatment yielded consistent results, and age did not affect the risk of influenza with ICS use.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)
Article
Respiratory System
Hong Chen, Yulin Feng, Ke Wang, Jing Yang, Yuejun Du
BMC PULMONARY MEDICINE
(2020)
Article
Respiratory System
Jian Luo, Ke Wang, Dan Liu, Bin-Miao Liang, Chun-Tao Liu
RESPIRATORY RESEARCH
(2016)
Article
Immunology
Jun Cui, Cheng Chen, Xiao Zhou, Wenju Shan, Yuhong Jian, Panpan Li, Yang Sun, Wei Yi
Summary: Bone marrow mesenchymal stem cells (BMSCs) are a promising therapy for sepsis, but metabolic syndromes threaten their effectiveness. This study investigated the potential of small extracellular vesicles from high-fat diet BMSCs in sepsis-induced liver-heart axis injury.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Binbin Zhu, Angyang Cao, Chunqu Chen, Weijian Zhou, Wenjun Luo, Yu Gui, Qinwen Wang, Zhipeng Xu, Jianhua Wang
Summary: GM6001 alleviates postoperative cognitive deficits and neuroinflammation, preserves blood-brain barrier integrity, and rescues aquaporin-4 mislocalization. MMP-9 inhibition plays a dual role in cognitive protection through direct anti-neuroinflammatory effects and regulation of aquaporin-4 membrane distribution.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Anika Sood, Valencia Fernandes, Kumari Preeti, Shruti Rajan, Dharmendra Kumar Khatri, Shashi Bala Singh
Summary: S1PR2 inhibitor improves cognitive function and skews microglia toward anti-inflammatory phenotype in type 2 diabetic mice, promising to be a potential therapy for neuroinflammation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Haochun Guo, Ran Yu, Haijun Zhang, Wanpeng Wang
Summary: Radiation therapy is an effective treatment for thoracic malignancies, but it can cause radiation-induced lung injury (RILI), including radiation pneumonitis (RP) and radiation pulmonary fibrosis (RPF). The damage to normal lung cells during radiation treatment leads to a pulmonary inflammatory response, resulting in RP and RPF.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Guanghui Wang, Haotian Zheng, Yunzhi Xiang, Yadong Wang, Kai Wang, Xiaoyang Ren, Jiajun Du
Summary: This study identified a T-cell synthetic driver-associated prognostic model that accurately predicted prognosis and effectiveness of immunotherapy in LUAD patients. It also highlighted the role of LDHA in promoting tumor cell proliferation, invasion, and resistance to treatment, as well as its involvement in immune escape within the tumor microenvironment. These findings provide a promising new therapeutic strategy for LUAD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Bowen Wei, Aihua Wang, Wei Liu, Qingyun Yue, Yihua Fan, Bin Xue, Siwei Wang
Summary: This study systematically analyzed the association between pSS and cuproptosis, established a predictive model based on 5 genes, explored the pathogenic mechanisms and novel therapeutic strategies for pSS, and identified EED, CBL, and NFU1 as potential targets for treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Nusrit Iqbal Andrabi, Aminur R. Sarkar, Syed Assim Haq, Diljeet Kumar, Dilpreet Kour, Diksha Saroch, Sanket Kumar Shukla, Ajay Kumar, Asha Bhagat, Asif Ali, Gurleen Kour, Zabeer Ahmed
Summary: Koenimbine and its novel semi-synthetic derivative 1G demonstrate significant anti-inflammatory effects by downregulating the nuclear factor kappa-B (NF-kappa B) signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Jing-Mei Lu, Xiang Xu, Fumie Aosai, Ming-Yue Zhang, Lian-Xun Piao
Summary: This study found that arctiin can improve allergic acute liver injury caused by T.g.HSP70 by inhibiting TLR4 signaling and reducing the production of inflammatory mediators.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Minxuan Xu, Fang Shi, Yongshen Gao, Shumei Han, Chensuo Huang, Qinsheng Hou, Xiaoweng Wen, Bengshi Wang, Zhenyu Zhu, Lei Zou, Mingxin Xiong, Wei Dong, Jun Tan
Summary: There is a growing body of research highlighting the involvement of metabolic imbalance and the inflammatory response in the advancement of colitis. This study recognizes arabinose as a significant protector of the intestinal mucosal barrier, reducing damage to the intestines. In addition, lower levels of arabinose in the bloodstream are associated with a higher severity of inflammatory bowel disease and colorectal cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yueqing Han, Haoxin Song, Yanshan Li, Rongxin Li, Ling Chen, Bo Gao, Yijun Chen, Shuzhen Wang
Summary: The combination of tetracycline antibiotics, demeclocycline (D), chlortetracycline (C), and minocycline (M), showed therapeutic potential against liver fibrosis by inhibiting the activation of hepatic stellate cells and the MAPK signaling. This study suggests that tetracyclines may be repurposed for the treatment of liver fibrosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yu Li, Hailing Liu, Danwen Zhao, Danjie Zhang
Summary: Chronic stress can lead to lung injury, with the spleen playing a crucial role. This study found that the spleen contributes to chronic restraint stress-induced lung injury, and splenic CD11b+ cells may be an important factor in this process.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yingqian Mi, Mengyan Tang, Qiong Wu, Yinan Wang, Qihui Liu, Pei Zhu, Xiaoyang Xue, Yuntong Liu, Xinyu Chai, Yuyang Hou, Dongmei Yan
Summary: BCG therapy can induce macrophage polarization to the M1 type, and NMAAP1 plays a crucial role in this process by regulating glycolysis and HIF-1α expression. This promotes the antitumor effect of macrophages.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Xiaosheng Liu, Tingxia Lv, Xiuxia Li, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li
Summary: LLDT-8 exhibits notable efficacy in alleviating immune activation in both an in vivo animal model and in vitro human cell experiments, suggesting its potential as a drug for managing systemic immune activation associated with SIV/HIV infection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Honghong Yu, Qi Li, Huimin Zhu, Chang Liu, Weiwei Chen, Lingyun Sun
Summary: The activation of the inflammasome plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE), and mesenchymal stem cells (MSC) have been shown to alleviate SLE by suppressing inflammasome activation. This study found that the NLRP3 inflammasome was activated in macrophages from SLE patients and mice, and its activation correlated with disease activity. After MSC transplantation, the severity of SLE was reduced, and NLRP3 inflammasome activation was inhibited. These findings suggest that MSC suppress inflammasome activation and provide a potential therapeutic target for SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Wei Zhou, Dan Zeng, Shunan Liu, Yunxia Huang, Fenglin Lv, Weikang Zhou
Summary: This study found that inhibiting HDAC3 can protect the skin from atopic dermatitis by activating the Nrf2 transcription to upregulate Nrf2/HO-1 signaling pathway activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)